Premium
EFFECT OF VESSILEN ® , A NEW FORMULATION OF ADELMIDROL AND SODIUM HYALURONATE, ON OVERACTIVE URINARY BLADDER SYNDROME
Author(s) -
Cuzzocrea Salvatore,
Peritore Alessio,
Crupi Rosalia,
Campolo Michela,
Siracusa Rosalba,
Cordaro Marika,
Filippone Alessia,
Esposito Emanuela
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.824.10
Subject(s) - overactive bladder , spinal cord injury , medicine , urinary system , urology , spinal cord , urinary bladder , neuroregeneration , central nervous system , pathology , alternative medicine , psychiatry
The disruption of coordinated control between the brain, spinal cord and peripheral nervous system caused by spinal cord injury leads to several secondary pathological conditions, including lower urinary tract dysfunctions. In fact, a disability after SCI is urinary dysfunction, which could be attributable to lack of neuroregeneration of supraspinal pathways that control the bladder function. As a consequence, individuals develop overactive urinary bladder (OAB). The aim of the current study was to explore the effects of vessilen®, a new formulation of 2% adelmidrol + 0.1% sodium hyaluronate, in OAB generated after SCI in mice. Mice were treated with vessilen® (100ml/mouse, intravesical) daily for 48 h and 7 days after SCI. Vessilen® reduced significantly mast cells degranulation and down regulated NFκB pathway in the bladder after SCI both at 48h and 7 days. Moreover vessilen® was able to reduce NGF expression suggesting an association between neurotrophins and bladder pressure. Moreover, 7 days after SCI, bladder was characterized by a considerable bacterial infection and proteinuria, surprisingly vessilen® reduced significantly both parameters. These data show the protective roles of vessilen® in OAB following SCI, highlighting a potential therapeutic target for controlling OAB, making a significant impact on improving overall quality of life. Support or Funding Information no funding This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .